Healthcare Market Research Reports & Industry Analysis

Publications found: 73,128
Sort by:

Physician Views: Life-cycle Management Strategies in Multiple Sclerosis – Can New Versions of Copaxone, Avonex Drive Market Share Retention?

US$ 695.00

... respectively, in 2013, it is not surprising to see both companies implementing life-cycle management strategies in the key US market. The performance of the two products ... earlier Physician Views polls run by FirstWord did support the view that Teva would meet its expectations. Sentiment towards the strategy ...

March 2014 -

Multiple Sclerosis - KOL Insight and Consensus Outlook Modules

US$ 7,495.00

... comprehensive FirstWord research is available in two comprehensive modules: The KOL Insight: Multiple Sclerosis module provides a complete review and is enhanced with ... the date of purchase Such updates are incorporated throughout the KOL reports ensuring the change is reflected in every aspect of the report ...

March 2014 183 pages

Hospital Market in India 2014

US$ 950.00

... in 0-2 business days after order is placed. Netscribes’ latest market research report titled Hospital Market in India 2014 captures the largest segment of the overall domestic healthcare ...

March 2014 108 pages

Physician Views: Can Bayer deliver on its Xarelto bullishness?

US$ 695.00

... of warfarin) with Xarelto retaining its current level of market share. Bayer's confidence in Xarelto is clearly high, adds Leuchten, pointing to the ... this week's Physician Views poll revisits the novel anticoagulant market and surveys cardiologists and general practioners/primary care physicians (GP/PCPs) ...

March 2014 -

The Reality of Market Access in Europe: the role of Health Technology Assessment

US$ 595.00

... early stages of being coordinated into a system across Europe. In The Reality of Market Access in Europe: the role of Health Technology Assessment, FirstWord skilfully addresses ... Benefits Attitudes to drug reimbursement have been shaped by economics. In The Reality of Market Access in Europe: the role of Health Technology Assessment, you will: Understand ...

March 2014 82 pages

China Chinese Patent Medicine Industry Report, 2013-2016

US$ 2,200.00

... , affected by access restrictions and differences in medical health concept, Chinese patent medicine is still only sold as health care product. However, the ... Report, 2013-2016 mainly covers the followings: Introduction to China’s Chinese patent medicine industry chain as well as domestic and foreign policies ...

March 2014 102 pages

Physician Views: What role will device development play in the future GLP-1 agonist market?

US$ 695.00

... will provide payers to extract greater discounting and rebates – will also play a role in market development. Nevertheless, AstraZeneca is hoping that a new pen device will ... and/or patient preference towards this drug class as a whole? What advantage they perceive would be provided by an auto-injector pen ...

March 2014 -

Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?

US$ 695.00

... available (its approval in the US market is anticipated in Q3). Predicting an accurate view of future market dynamics remains difficult at this point, however ... expect to prescribe a once-weekly product with comparable efficacy to Victoza (i.e. dulaglutide) if that product had: A comparable weight-loss profile; ...

March 2014 -

United States and Japan – Proton Therapy Market, Patients & Forecast

US$ 1,475.00

... for more proton therapy centers are very high. This report is divided into 14 Chapters A. United States Proton Therapy Market – Actual ... IBA Proton Therapy 2. Optivus Proton Therapy 3. Hitachi Proton Therapy 4. Mevion Proton Therapy 5. Varian Proton Therapy Chapter No. 11 speaks of Proton Therapy centers ...

March 2014 75 pages

Global RNA Interference (RNAi) Therapy Market Outlook 2018

US$ 1,800.00

... and in industry. Since discovery, RNA interference is considered to be a turning point for molecular ... Global RNAi Therapy Report Highlights: Introduction & Need Analysis of RNAi Therapy Benefits & Drug Delivery Mechanics Related to RNAi RNAi Therapy Market Insight Ongoing Clinical Trail/Pipeline for RNAi ...

March 2014 300 pages

Global Endoscopy Market Report: 2014 Edition

US$ 800.00

... demographic trends. The market for endoscopy products is highly competitive with several players operating both at a global and regional level. ... Nephew, and Karl Storz, among others. The report “Global Endoscopy Market” analyzes the development of this market, with a focus on its segments including: ...

February 2014 54 pages

Physician Views: A closer look at Gilead's spectacular Sovaldi launch

US$ 695.00

... accounted for around 70 percent of usage to date. Genotype 1 patients are viewed as being a key population for all-oral therapies (which dispense ... availability may have on new patient diagnosis rates. This week's Physician Views poll asks US and EU-based gastroenterologists, hepatologists and infectious disease ...

February 2014 -

Innovative Drug Delivery Systems Opportunities For Generic & Specialty Pharmaceutical Companies

US$ 2,500.00

There are more than 1400 sustained or controlled release drugs have been approved all over the world. Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall ...

February 2014 91 pages

Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral Drugs and Biologics to Change Future Treatment Paradigm

US$ 2,500.00

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded ... OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis ...

February 2014 55 pages

Therapeutic Class Overview: Treating Refractory Hematological Malignancies

US$ 2,500.00

... decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs – Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting ...

February 2014 43 pages

Therapeutic Class Overview: Emergence of Biogenerics Era in Japan - it's time to welcome Antibody Biosimilars of Foreign Origins Soon

US$ 2,500.00

... map for biosimilars space, at this time we see Sandoz, JCR, Meiji Seika Pharma, Fuji Film Kyowa Kirin Biologics, Nippon Kayaku, Nichi Iko, Yoshindo etc. to be amongst the key players in biogenerics business in Japan. It is also noteworthy ...

February 2014 31 pages

Therapeutic Class Overview: New avatars of microbes super bugs a growing threat worldwide

US$ 1,500.00

... infections during the treatment were not available. If that fails, the gains ... super infections” warranting need for new classes of antibiotics and other preventive/therapeutic approaches ... Gram Negative infections and CRE. Pipeline of novel targets being used to develop new drugs to treat infections and resistance ...

February 2014 12 pages

Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in The Treatment Paradigm of Prostate Cancer

US$ 2,500.00

... bigger for newer options than late stage if they succeed.In coming years, we expect second generation antiandrogens (Androgen synthesis inhibitors/Androgen receptor inhibitors, Xtandi, ARN-509, ODM-021, Zytiga, TAK-700, TOK-001) to replace ...

February 2014 44 pages

Physician Views: How will neurologists embrace Teva's new version of Copaxone? What about potential generic versions later this year?

US$ 695.00

... using it for a long time with no real safety issues." How neurologists utilise any generic version of Copaxone, should one or multiple ... about potential usage of such a product. This week's Physician Views poll will ask US-based neurologists: Approximately what percentage of existing Copaxone patients do you ...

February 2014 -

Global Peptide Therapeutics Market & Pipeline Insight

US$ 2,400.00

... in the pre-clinical studies. There are many applications of the peptide drugs. The most popular and dominant segments include cancer ... demand for peptide drugs, this market is expected to grow at a CAGR of 9-10% to reach approximately USD 27.3 billion by 2018. “Global Peptide Therapeutics Market & Pipeline ...

February 2014 1350 pages

Outsourced Customer Care Services Market Analysis And Segment Forecasts To 2020

US$ 4,950.00

... the global outsourced customer care services market on the basis of service activity and region: Outsourced Customer Care Service Activity Outlook (Revenue, USD Million, 2012 – 2020) Customer Interaction Customer Service Sales Marketing Technical Support ...

February 2014 77 pages

Global Extremities Market Report: 2013 Edition

US$ 800.00

... surgeons and increase patient awareness. Ongoing mergers and acquisitions and development of innovative extremity devices and implants are the key trends observed in this market. This report analyzes the development of the global extremities market, with a focus on its segments including: ...

February 2014 57 pages

Physician Views: Assessing the launch of GlaxoSmithKline's Breo Ellipta

US$ 695.00

... a notable caveat could be that it is waiting to step up promotion of Breo when it launches a second new COPD drug – Anoro Ellipta – which was approved ... has delivered lower-than-expected uptake since launching in late 2013, this week's Physician Views poll will ask US-based pulmonologists: Approximately how ...

January 2014 -

Physician Views: As momentum grows for the SGLT-2 inhibitor class, can AstraZeneca's Farxiga move into Invokana's slipstream?

US$ 695.00

... to be seen if Farxiga can find a suitable position in Invokana's slipstream. While physicians have embraced the SGLT-2 class – with sizeable usage reported ... to side-effect concerns) could also limit uptake. Nevertheless, with momentum growing for the SGLT-2 class, there could be an opportunity for AstraZeneca ...

January 2014 -

DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

US$ 500.00

... Cancer Stem Cell Inhibitors- from OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) also need a close watch. On M & A front (Table 11), DSP’s R & D collaboration with Edison pharma ...

January 2014 14 pages

TAKEDA , Challenges Ahead for its New European Presiden

US$ 500.00

... failure a moderate Positive- while development of Brexpiprazole looks a close competitor!.........Vedolizumab (MLN0002, UR, US/EU, vedolizumab, α4β7 integrin inhibitor, Ulcerative colitis / Crohn’s disease) and MLN-9708 (PhIII, Multiple Myeloma) are the most promising late ...

January 2014 24 pages

World Point-of-Care Testing Market 2014: Country Segment Forecasts, Market Shares, Emerging Technologies, Competitive Strategies, Growth Opportunities

US$ 20,400.00

This new report from Venture Planning Group contains 1,230 pages, 343 tables and provides forecasts for 300 tests by country and market segment, as well as sales and market shares for reagent and instrument suppliers.

January 2014 1230 pages

World Point-of-Care Diagnostic Testing Market 2014

US$ 20,400.00

... consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient. Market Segmentation Analysis Review of the ... Emergency Rooms Operating/Recovery Suites ICUs/CCUs Cancer Clinics Ambulatory Care Centers Surgery Centers Nursing Homes Birth Centers and ...

January 2014 1230 pages

India Specialty Clinics Market Opportunity Analysis 2018

US$ 800.00

... business model of single clinics specialized in particular domain would lead the growth in the Indian healthcare industry. “India Specialty Clinics Market Opportunity Analysis 2018” research report by KuicK Research is an intriguing text that gives detailed facts and analysis on latest developments in the Indian Specialty Clinics market ...

January 2014 96 pages

Pharmaceuticals and Food Anti-Counterfeiting Technologies Market Analysis By Application (Food, Pharmaceuticals), By Technology (Authentication, Inks and Dyes, Holograms, Watermarks, Taggants, Others, Trace and Track, Bar Codes, RFID) And Segment Forecasts To 2020

US$ 4,450.00

... Track Bar Codes RFID (Radio Frequency Identification) Pharmaceuticals and Food Anti-Counterfeiting Technologies Application Outlook, Food Pharmaceuticals Pharmaceuticals and Food Anti-Counterfeiting Technologies Regional Outlook, North America Europe Asia Pacific ...

January 2014 83 pages

Bone Grafts: Market Research Report

US$ 4,950.00

This report analyzes the worldwide markets for Bone Grafts in US$ Million. The US market for Bone Graft Substitutes is also analyzed by the following segments: ... 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary ...

January 2014 187 pages

Advancements in Prenatal Screening Trends: Market Research Report

US$ 1,450.00

The report illustrates the advancements in Prenatal Screening with a brief note on emerging developments in non-invasive prenatal screening, emerging developments in non-invasive prenatal testing, and emerging trends in the US non-invasive prenatal screening market. Prenatal diagnosis enables detection of ...

January 2014 33 pages

Aircraft Health Monitoring System Trends: Market Research Report

US$ 950.00

... report analyzes and presents an overview of Aircraft Health Monitoring Systems market worldwide. Supported with 1 market data table, the report provides a review of market trends, growth drivers, and strategic industry activities of major companies worldwide. In addition, ...

January 2014 14 pages

Neural Control Trends: Market Research Report

US$ 950.00

... and the prospective application areas. In addition, the report also expounds the drawbacks of cyborg insects. Neural control, also known as neural interaction or neural interfacing, is touted to emerge as a revolutionary technology and a new electrophysiological approach in the human-machine interaction ...

January 2014 11 pages

Virus-Like Particles (VLPs) Trends: Market Research Report

US$ 950.00

The report analyzes and presents an overview of Virus-Like Particles (VLPs) market worldwide. 'Virus-like particles or VLPs bear high structural resemblance to viruses, though completely non-infectious in nature due to the absence of viral genetic material. While lacking the DNA material, ...

January 2014 12 pages

Digital Health Quarterly 4Q 2013 2Q 2014

US$ 1,500.00

... of these entities on future market and technological developments. Parks Associates’ digital health technology coverage includes analysis of four major industry segments. ... healthily and allay anxiety among family members Wellness & Fitness: Digital and mobile products and services that help drive preventive ...

January 2014 18 pages

2014 U.S. Home Health Care Services Industry-Capital & Expenses Report

US$ 149.00

The 2014 U.S. Home Health Care Services Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry ... , inventories, rentals, and other expenses nationally and for all 50 U.S. States and up to 900 metro areas. Expenses categories include materials used, ...

December 2013 213 pages

2014 U.S. Medical Laboratories Industry-Capital & Expenses Report

US$ 149.00

The 2014 U.S. Medical Laboratories Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the cost of materials, capital expenditures, inventories, ...

December 2013 161 pages

2014 U.S. Nursing Care Facilities Industry-Capital & Expenses Report

US$ 149.00

The 2014 U.S. Nursing Care Facilities Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics ... , inventories, rentals, and other expenses nationally and for all 50 U.S. States and up to 900 metro areas. Expenses categories include materials used ...

December 2013 219 pages

2014 U.S. Offices of Certified Public Accountants Industry-Capital & Expenses Report

US$ 149.00

The 2014 U.S. Offices of Certified Public Accountants Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the cost of materials, capital ...

December 2013 219 pages

2014 U.S. Offices of Lawyers Industry-Capital & Expenses Report

US$ 149.00

The 2014 U.S. Offices of Lawyers Industry-Capital & Expenses Report, published annually by Barnes Reports, contains timely and accurage industry statistics, forecasts and demographics. The report features 2014 current and 2015 forecast estimates on the cost of materials, capital expenditures, inventories, ...

December 2013 221 pages

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)

US$ 3,390.00

... lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types—childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia. The acute lymphocytic/lymphoblastic leukemia therapeutics market ...

December 2013 157 pages

Booming IVF Market in India

US$ 1,000.00

... is increasing at an alarming rate. According to RNCOS’ report “Booming IVF Market in India”, the IVF market is poised to witness impressive CAGR of around 14% over ... region-wise i.e. their penetration across East/West/North/South India; their structure i.e. chain, independent and hospital-based; the number of ...

December 2013 50 pages

Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?

US$ 695.00

... radiopharmaceutical - see In Focus: Bayer's M&A catalyst – FirstWord speaks to Xofigo's lead investigator. Impressive Q3 sales, and confirmation that Bayer and Algeta ... gain a better understanding of the outlook for Xofigo, this week's Physician Views poll will ask US-based urologists and oncologists... Where ...

December 2013 -

Physician Views: Sanofi's successor to Lantus - are endocrinologists impressed?

US$ 695.00

... hypoglycaemia – currently known as Insulin U300 – is the most important product in Sanofi's late-stage R&D pipeline. With submission to regulators expected next year ... in selected European markets and Japan – there appears to be an opportunity for Sanofi to push home an advantage with U300, particularly by building on the entrenchment ...

December 2013 -

Production of Niacin in China

US$ 1,192.00

... , which is in great demand in the fast-growing feed industry. The production of niacin in China started in the 1960s with small output. After the 20th ... experienced large capacity expansion, pulling down their prices. Most niacin producers in China adopt 3-picoline, whose capacity has risen from 20,000t ...

November 2013 13 pages

Enanta- It is just the beginning of good news

US$ 90.00

... SVR12 data of SAPPHIRE-I –oral regimen (ENTA’s /ABT-450 boosted Abbvie’s ritonavir, ... data from the first of six Phase III HCV trial of ENTA/AbbVie's using its oral IFN free regimen. ... 1) and regulatory filing in 2nd half of 2014 we expect ENTA shares to appreciate further. We are positive on the PhIII study ...

November 2013 2 pages

Competitor Analysis: Janus Kinase (JAK) and spleen tyrosine kinase (syk) Inhibitors

US$ 529.00

... developments in the pipeline of inhibitors of the janus-associated kinase (JAK) and of spleen tyrosine kinase provides a competitor evaluation in the field of active ... ) are made up of a family of four cytoplasmic tyrosine kinases—JAK1, JAK2, JAK3, and TYK2—that play pivotal roles in the signaling pathways ...

November 2013 69 pages

India IVF Treatment Market Outlook 2018

US$ 600.00

... IUI, IVF, and ICSI (intra cytoplasmic sperm injection). India has become one of the favored destinations for infertility treatments such as IVF due to several ... health care system. “India IVF Treatment Market Outlook 2018” report by KuicK Research gives comprehensive insight on following aspects related to booming IVF treatment market in India: Market Overview IVF Treatment Market Potential Total Fertility ...

November 2013 54 pages

Global Hearing Aid Market Report: 2013 Edition

US$ 800.00

... , certain people have relative insensitivity to sound. Such situation is termed as hearing impairment. The increase in volume above the usual sound levels ... serious challenges in terms of social stigma and rise in price pressure. The report on global hearing aid market contains a comprehensive analysis of the ...

November 2013 69 pages

Filters

Search

Categories

1,254
193
212
1,214
34
241
217
160
142
64,306
1,332
1,265
2,373
185

Publishers

649
541
179
32
1
1,509
34
239
366
389
103
148
348
3
202
3
6
1,623
487
80
123
208
112
31
1,049
383
23
40
68
513
953
34
29,954
248
501
3,036
1
1
2
3
16
536
361
1
1,357
1,806
60
1,696
8
7,373
2,206
6,530
321
66
3
36
200
29
29
143
42
83
3
281
85
20
6
43
14
1
178
48
359
36
44
10
11
18
168
385
8
3
18
58
913
6
89
12
24
15
1,286
229
128
386
3
74
10
119
227
46
474
26
133
4

Regions

201
97
86
75
74
50
48
42
41
40
36
36
35
31
30
29
28
27
27
26
24
24
18
17
17
17
17
16
16
15
13
12
12
11
10
9
8
8
8
7
7
6
6
6
6
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
798
552
2
2
2
118
198
104
61
38
709
75
136
531
215
1,137
66,824

Price

—

Date

—

Pages

—

Offers

1
280
1
1